Loading…
Loading…
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) is anticipated to post its Q1 2027 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.1689 per share and revenue of $7.1469 billion for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2027 earning report for
Japanese drugmaker Takeda Pharmaceutical's dengue vaccine QDENGA has been approved by India's drug regulator, making it the first dengue vaccine to be approved in the country, the company's Indian unit said on Monday.
Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) on Friday revealed encouraging secondary data from two pivotal Phase 3 trials evaluating zasocitinib, its next-generation oral treatment for moderate-to-severe plaque psoriasis.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance acro.
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia's plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a.
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for TAK and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.